Literature DB >> 16190761

Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors.

Sheeba Varghese1, Deepak Gupta, Tiffany Baran, Anchalee Jiemjit, Steven D Gore, Robert A Casero, Patrick M Woster.   

Abstract

The reversible acetylation of histones is critical for regulation of eukaryotic gene expression. The histone deacetylase inhibitors trichostatin (TSA, 1), MS-275 (2) and suberoylanilide hydroxamic acid (SAHA, 3) arrest growth in transformed cells and in human tumor xenografts. However, 1-3 suffer from lack of specificity among the various HDAC isoforms, prompting us to design and synthesize polyaminohydroxamic acid (PAHA) derivatives 6-21. We felt that PAHAs would be selectively directed to chromatin and associated histones by the positively charged polyamine side chain. At 1 microM, compounds 12, 15 and 20 inhibited HDAC by 74.86, 59.99 and 73.85%, respectively. Although 20 was a less potent HDAC inhibitor than 1, it was more potent than 2, more effective as an initiator of histone hyperacetylation, and significantly more effective than 2 at re-expressing p21Waf1 in ML-1 leukemia cells. On the basis of these results, PAHAs 6-21 represent an important new chemical class of HDAC inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16190761      PMCID: PMC3554812          DOI: 10.1021/jm0505009

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

Review 1.  Terminally alkylated polyamine analogues as chemotherapeutic agents.

Authors:  R A Casero; P M Woster
Journal:  J Med Chem       Date:  2001-01-04       Impact factor: 7.446

Review 2.  Histone deacetylases and cancer: causes and therapies.

Authors:  P Marks; R A Rifkind; V M Richon; R Breslow; T Miller; W K Kelly
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

3.  Different accessibilities in chromatin to histone acetylase.

Authors:  L S Cousens; D Gallwitz; B M Alberts
Journal:  J Biol Chem       Date:  1979-03-10       Impact factor: 5.157

4.  Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

Authors:  William Kevin Kelly; Owen A O'Connor; Lee M Krug; Judy H Chiao; Mark Heaney; Tracy Curley; Barbara MacGregore-Cortelli; William Tong; J Paul Secrist; Lawrence Schwartz; Stacy Richardson; Elaina Chu; Semra Olgac; Paul A Marks; Howard Scher; Victoria M Richon
Journal:  J Clin Oncol       Date:  2005-05-16       Impact factor: 44.544

Review 5.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.

Authors:  Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

6.  Polyamines inhibit the yeast histone deacetylase.

Authors:  Q A Vu; D E Zhang; Z C Chroneos; D A Nelson
Journal:  FEBS Lett       Date:  1987-08-10       Impact factor: 4.124

7.  Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine.

Authors:  Rohit B Kolhatkar; Sujit K Ghorai; Clifford George; Maarten E A Reith; Aloke K Dutta
Journal:  J Med Chem       Date:  2003-05-22       Impact factor: 7.446

8.  A novel polyamine analog (SL-11093) inhibits growth of human prostate tumor xenografts in nude mice.

Authors:  Benjamin Frydman; Carl W Porter; Yulia Maxuitenko; Aparajita Sarkar; Subhra Bhattacharya; Aldonia Valasinas; Venodhar K Reddy; Nick Kisiel; Laurence J Marton; Hirak S Basu
Journal:  Cancer Chemother Pharmacol       Date:  2003-04-15       Impact factor: 3.333

Review 9.  Trichostatin A-like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view.

Authors:  Tamara Vanhaecke; Peggy Papeleu; Greetje Elaut; Vera Rogiers
Journal:  Curr Med Chem       Date:  2004-06       Impact factor: 4.530

10.  Long-chain polyamines (oligoamines) exhibit strong cytotoxicities against human prostate cancer cells.

Authors:  Aldonia Valasinas; Venodhar K Reddy; Andrei V Blokhin; Hirak S Basu; Subhra Bhattacharya; Aparajita Sarkar; Laurence J Marton; Benjamin Frydman
Journal:  Bioorg Med Chem       Date:  2003-09-01       Impact factor: 3.641

View more
  14 in total

Review 1.  Recent advances in the development of polyamine analogues as antitumor agents.

Authors:  Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

2.  Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group.

Authors:  Youxuan Li; Patrick M Woster
Journal:  Medchemcomm       Date:  2015-04-01       Impact factor: 3.597

3.  Use of polyamine derivatives as selective histone deacetylase inhibitors.

Authors:  Patrick M Woster
Journal:  Methods Mol Biol       Date:  2011

Review 4.  Polyamines and cancer: implications for chemotherapy and chemoprevention.

Authors:  Shannon L Nowotarski; Patrick M Woster; Robert A Casero
Journal:  Expert Rev Mol Med       Date:  2013-02-22       Impact factor: 5.600

5.  A novel histone deacetylase inhibitor prevents IL-1beta induced metabolic dysfunction in pancreatic beta-cells.

Authors:  Laura Susick; Thulani Senanayake; Rajakrishnan Veluthakal; Patrick M Woster; Anjaneyulu Kowluru
Journal:  J Cell Mol Med       Date:  2009-08       Impact factor: 5.310

6.  Polyamine-based small molecule epigenetic modulators.

Authors:  Shiv K Sharma; Stuart Hazeldine; Michael L Crowley; Allison Hanson; Ross Beattie; Sheeba Varghese; Thulani M D Senanayake; Aiko Hirata; Fusao Hirata; Yi Huang; Yu Wu; Nora Steinbergs; Tracey Murray-Stewart; Ian Bytheway; Robert A Casero; Patrick M Woster
Journal:  Medchemcomm       Date:  2011-11-26       Impact factor: 3.597

7.  Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.

Authors:  Sheeba Varghese; Thulani Senanayake; Tracey Murray-Stewart; Kim Doering; Alison Fraser; Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2008-03-19       Impact factor: 7.446

Review 8.  Polyamine analogues targeting epigenetic gene regulation.

Authors:  Yi Huang; Laurence J Marton; Patrick M Woster; Robert A Casero
Journal:  Essays Biochem       Date:  2009-11-04       Impact factor: 8.000

Review 9.  Design of polyamine-based therapeutic agents: new targets and new directions.

Authors:  M D Thulani Senanayake; Hemali Amunugama; Tracey D Boncher; Robert A Casero; Patrick M Woster
Journal:  Essays Biochem       Date:  2009-11-04       Impact factor: 8.000

Review 10.  Targeting polyamine metabolism for cancer therapy and prevention.

Authors:  Tracy R Murray-Stewart; Patrick M Woster; Robert A Casero
Journal:  Biochem J       Date:  2016-10-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.